Park Dental Partners Inc. (PARK) Next Earnings Date & Expected ±12.4% Move

Per the Roarable RQD rating, PARK carries an RQD Score of 56 out of 100, a letter grade of D+, and a verdict label of "Roarable Sell — Weak Fundamentals / Trim." The five pillars break down as follows. The Fundamental Cash Engine scores 10 of 20, with ROIC at 0% and FCF yield at 0%, indicating that the source data does not show the business currently generating returns on capital or free cash flow. Whale 13F Flow scores 9 of 20, reflecting institutional accumulation and options positioning assessed as weak. Insider Conviction scores 9 of 20, covering SEC Form 4 and Congressional PTR cluster flow. Macro Regime Fit scores 15 of 20, with a beta of 1.0 and a sector sensitivity assessment. Forensic Balance Sheet scores 13 of 20, supported by an Altman Z-Score of 2.5, a Piotroski F-Score of 6 out of 9, and a Debt/Equity ratio of 0.46.

For a prospective investor, the rating's implication is that the weakest pillar is the one most directly tied to earning a return: the cash engine. The balance sheet and macro-fit pillars are comparatively stronger, meaning the company is not flagged as financially distressed on the forensic measures provided, but the absence of positive ROIC and FCF yield means upside would depend on a change in operating performance that the source data does not demonstrate. Valuation tradeoffs are difficult to assess because P/E, forward P/E, EV/EBITDA, and EPS are not available in source data. The stock's 52-week range of $9.53 to $26.79 with a current price of $20.06 shows substantial price volatility, while the rating itself signals that the fundamentals do not currently support the price trajectory. This is an analytical framing, not personalized advice.

Per the SEC financials, the single reported period (FY 2025) shows $0.0M in revenue, operating income, and net income, with EPS and FCF listed as N/A, so profitability and margins cannot be assessed from reported figures. Gross, operating, and net margins are each listed as 0%, and ROIC is 0%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 6 out of 9, and Debt/Equity is 0.46. Reported cash of $25.2M exceeds reported debt of $10.1M for FY 2025. Trend direction across periods cannot be determined from a single reported period.

Per the recent news feed, the most prominent item is an announcement of dates for the third-quarter 2026 earnings release and conference call (Yahoo Finance and Stock Titan both reference a call on Nov. 13 at 8:30 a.m.). A second item reports that Park Dental Partners confirmed patient data was acquired in a network intrusion (Kalkine), which is a material operational and reputational risk watch item. Other items reference the stock's price action, including a 1.70% decline to $20.25 with a Bollinger Squeeze description, and a ParkOhio third-quarter webcast, which the source does not connect to Park Dental Partners and should be treated with caution given the name similarity.

Per the Butterfly Supply-Chain Graph, the proprietary signal is a LIQUIDITY_TAILWIND with a Macro Tailwind Score of 94/100, severity 93, and bullish direction. The signal cites a True Net Liquidity Index of $5,745.73B with a -0.64% 4-week rate of change, High-Yield OAS of +2 bps, and a rolling 5-year regression assigning PARK a 3.19x Net Liquidity beta (r = -0.19). Investors should note that this signal is macro-driven and is not corroborated by the company-level fundamentals, which the RQD rating scores as weak. The regression's low correlation (r = -0.19) also limits how much weight the beta estimate can carry.

Per the Butterfly Supply-Chain Graph, supply chain status is listed as NONE and the butterfly links array is empty, so no upstream or downstream dependencies are identified in the source data. Sector is Health Care and industry is Misc Health and Biotechnology Services, but no sector correlations beyond the liquidity regression are provided. Second-order bottlenecks cannot be mapped from the source data. The principal ripple the data does surface is the liquidity sensitivity: because the signal ties PARK's price behavior to Net Liquidity conditions, a change in Fed balance sheet, Treasury General Account, or Overnight RRP levels would be expected to transmit to the stock through that channel. The reported patient-data intrusion is a company-specific operational risk that may ripple through regulatory or customer-trust channels, but the source data does not quantify those effects.

• What are the company's products, customers, and revenue model, given that the source data reports $0.0M in revenue for FY 2025?
• Why are FY 2025 revenue, operating income, and net income reported as $0.0M, and is this a data-reporting gap or an accurate reflection of operations?
• What was the scope, timing, and financial impact of the patient-data network intrusion, and has it been resolved?
• What drives the discrepancy between the company's $25.2M cash and $10.1M debt position and the 0% ROIC and FCF yield?
• Are there any analyst estimates, insider transactions, or institutional holdings that would allow the consensus and smart-money dimensions to be assessed?